ArticleMycopathologia2020
Case-Case Comparison of Candida auris Versus Other Candida Species Bloodstream Infections: Results of an Outbreak Investigation in Colombia.
Article in Mycopathologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Global prevalence, mortality, and comorbidities of patients with diabetes mellitus and proven Candida auris emerging infection: a systematic review & meta-analysis.BMC infectious diseases · 2026Pooled it
- Mortality ofFrontiers in cellular and infection microbiology · 2026Pooled it
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Clinical characteristics, healthcare-associated exposures, and antifungal susceptibility patterns of Candida auris colonization and invasive infections: a retrospective observational study at a single center in Turkey.BMC infectious diseases · 2026Observational
- Comparison of candidemia caused by Candida auris and non-auris Candida spp.: a retrospective cohort study on clinical characteristics, risk factors, and antifungal resistance profiles.BMC infectious diseases · 2026Article
- Mortality ofJournal of fungi (Basel, Switzerland) · 2026Article
- mNGS-Supported Interpretation ofInfection and drug resistance · 2026Article
- Genomic epidemiology of Colombian resistantAntimicrobial agents and chemotherapy · 2025Article
- Risk factors associated withEpidemiology and infection · 2025Article
- Article
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.Mycopathologia · 2025Article
- Candida auris: a global pathogen that has taken root in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.Antimicrobial agents and chemotherapy · 2022Article
- Novel Environmental Niches forJournal of fungi (Basel, Switzerland) · 2022Article
- Invasive Candidiasis: Update and Current Challenges in the Management of This Mycosis in South America.Antibiotics (Basel, Switzerland) · 2022Review
- Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.mSphere · 2022Article
- Detection and Control of Fungal Outbreaks.Mycopathologia · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCandida auris is an emerging multidrug-resistant yeast that causes outbreaks in healthcare settings around the world. In 2016, clinicians and public health officials identified patients with C. auris bloodstream infections (BSI) in Colombian healthcare facilities. To evaluate potential risk factors and outcomes for these infections, we investigated epidemiologic and clinical features of patients with C. auris and other Candida species BSI.
methodsWe performed a retrospective case-case investigation in four Colombian acute care hospitals, defining a case as Candida spp. isolated from blood culture during January 2015-September 2016. C. auris BSI cases were compared to other Candida species BSI cases. Odds ratio (OR), estimated using logistic regression, was used to assess the association between risk factors and outcomes.
resultsWe analyzed 90 patients with BSI, including 40 with C. auris and 50 with other Candida species. All had been admitted to the intensive care unit (ICU). No significant demographic differences existed between the two groups. The following variables were independently associated with C. auris BSI: ≥ 15 days of pre-infection ICU stay (OR: 5.62, CI: 2.04-15.5), evidence of severe sepsis (OR: 3.70, CI 1.19-11.48), and diabetes mellitus (OR 5.69, CI 1.01-31.9).
conclusionPatients with C. auris BSI had longer lengths of ICU stay than those with other candidemias, suggesting that infections are acquired during hospitalization. This is different from other Candida infections, which are usually thought to result from autoinfection with host flora.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.